TrialDiabetes, obesity & metabolism2013

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.

T Heise et al.PubMed ↗Publisher ↗

No numbers read from the abstract.